Search - tctmd.com

Displaying 121 - 140 of 389

Sort: Relevancy | Date

Presentation TCT 2016

2016 DAPT Update: Evidence and Guidelines

Presenter: Sripal Bangalore, George D. Dangas, Adnan K. Chhatriwalla

November 01, 2016

Presentation TCT 2016

Bioabsorbable Vascular Scaffolds: Landscape in 2016

Presenter: Sripal Bangalore, George D. Dangas, Alexandre Abizaid

November 01, 2016

‘Promising’ SENTINEL Cerebral Protection in TAVR Collects Debris but Misses Primary Endpoint

News Conference News TCT 2016

Sentinel Cerebral Protection Device in TAVR ‘Promising’ but Trial Misses Primary Endpoint

Shelley Wood

November 01, 2016

News Conference News TCT 2016

TAVR Provides ‘Acceptable’ Outcomes in Low-Flow, Low-Gradient Aortic Stenosis Patients With Poor Ventricular Function

Todd Neale

November 01, 2016

News Industry News TCT 2016

Dedicated Stent Study Conducted in Women and Minority Assesses Risks of Adverse Cardiovascular Events Following Coronary Stent Procedures

November 01, 2016

News Conference News TCT 2016

CMR Subanalysis of EXPLORE May Help Pinpoint Which CTO Regions Benefit From PCI

Yael L. Maxwell

November 01, 2016

Presentation TCT 2016

My Most Challenging Case 2016: STEMI with Multivessel Disease

Presenter: Shao-Liang Chen, Ajay J. Kirtane, Manish A. Parikh, Bo Xu, Ning Guo

October 31, 2016

Presentation TCT 2016

Complications 5. Bleeding after TAVR: Incidence, Prognostic Importance, Predictors, and Associations

Presenter: Neil E. Moat, John G. Webb, Philippe Généreux

October 31, 2016

Presentation TCT 2016

Strategies to Reduce the Frequency of New Pacemakers After TAVR: Imaging, Procedural, and Device-Related Factors

Presenter: Neil E. Moat, John G. Webb, Ian T. Meredith

October 31, 2016

Presentation TCT 2016

My Most Challenging Case 2016: Severe LV Dysfunction

Presenter: Shao-Liang Chen, Ajay J. Kirtane, Manish A. Parikh, Bo Xu, Qi Zhang

October 31, 2016

Presentation TCT 2016

Complications 4. Conduction Disturbances: Clinical Implications of New LBBB and New Pacemakers After TAVR

Presenter: Neil E. Moat, John G. Webb, Marina Urena

October 31, 2016

Presentation TCT 2016

Trial #9 - The Essentials ofIN.PACT SFA: 3-year Outcomes of a Paclitaxel-Coated Balloon for Femoropopliteal Lesions

Presenter: William A. Gray, Stephan Windecker, John R. Laird Jr.

October 31, 2016

Presentation TCT 2016

Strokes and TAVR: Is Stroke Frequency Declining? Etiologic Factors Clinical, Anatomic, Technique-related, and Device-specific

Presenter: Neil E. Moat, John G. Webb, Samir R. Kapadia

October 31, 2016

Presentation TCT 2016

My Most Challenging Case 2016: Chronic Total Occlusion

Presenter: Shao-Liang Chen, Ajay J. Kirtane, Manish A. Parikh, Bo Xu, Bin Zhang

October 31, 2016

Presentation TCT 2016

Complications 3. The Spectrum of Neurologic Events After TAVR: Insights From NeuroARC

Presenter: Neil E. Moat, John G. Webb, Alexandra J. Lansky

October 31, 2016

Presentation TCT 2016

ACT I Critique: Pro and Con

Presenter: William A. Gray, Stephan Windecker, Klaus D. Mathias

October 31, 2016

Presentation TCT 2016

Trial #8 - The Essentials ofThe ACT I Trial: Carotid Stenting vs Surgery In Asymptomatic Patients

Presenter: William A. Gray, Stephan Windecker, Kenneth Rosenfield

October 31, 2016

Presentation TCT 2016

The Landscape of Alternative Access Strategies for TAVR (Apical, Direct Aorta, Subclavian, Carotid, and Caval)

Presenter: Neil E. Moat, John G. Webb, Adam B. Greenbaum

October 31, 2016

Presentation TCT 2016

My Most Challenging Case 2016: Severe Calcified Lesion

Presenter: Shao-Liang Chen, Ajay J. Kirtane, Manish A. Parikh, Bo Xu, Juying Qian

October 31, 2016

Presentation TCT 2016

Complications 2. How to Prevent and Treat Transfemoral Access Site Complications

Presenter: Neil E. Moat, John G. Webb, Stephen R. Ramee

October 31, 2016

Advertisement

2016 DAPT Update: Evidence and Guidelines

Bioabsorbable Vascular Scaffolds: Landscape in 2016

Sentinel Cerebral Protection Device in TAVR ‘Promising’ but Trial Misses Primary Endpoint

TAVR Provides ‘Acceptable’ Outcomes in Low-Flow, Low-Gradient Aortic Stenosis Patients With Poor Ventricular Function

Dedicated Stent Study Conducted in Women and Minority Assesses Risks of Adverse Cardiovascular Events Following Coronary Stent Procedures

CMR Subanalysis of EXPLORE May Help Pinpoint Which CTO Regions Benefit From PCI

My Most Challenging Case 2016: STEMI with Multivessel Disease

Complications 5. Bleeding after TAVR: Incidence, Prognostic Importance, Predictors, and Associations

Strategies to Reduce the Frequency of New Pacemakers After TAVR: Imaging, Procedural, and Device-Related Factors

My Most Challenging Case 2016: Severe LV Dysfunction

Complications 4. Conduction Disturbances: Clinical Implications of New LBBB and New Pacemakers After TAVR

Trial #9 - The Essentials ofIN.PACT SFA: 3-year Outcomes of a Paclitaxel-Coated Balloon for Femoropopliteal Lesions

Strokes and TAVR: Is Stroke Frequency Declining? Etiologic Factors Clinical, Anatomic, Technique-related, and Device-specific

My Most Challenging Case 2016: Chronic Total Occlusion

Complications 3. The Spectrum of Neurologic Events After TAVR: Insights From NeuroARC

ACT I Critique: Pro and Con

Trial #8 - The Essentials ofThe ACT I Trial: Carotid Stenting vs Surgery In Asymptomatic Patients

The Landscape of Alternative Access Strategies for TAVR (Apical, Direct Aorta, Subclavian, Carotid, and Caval)

My Most Challenging Case 2016: Severe Calcified Lesion

Complications 2. How to Prevent and Treat Transfemoral Access Site Complications

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content